Who? | ||
| ||
W hen (at what a ge ) ? | ||
| ||
Familial pancreatic cancer kindred (without a known germline mutation) | Start at age 50 or 55* or 10 years younger than the youngest affected blood relative | |
Mutation carriers: For CDKN2A†, Peutz-Jegher syndrome, start at age 40; BRCA2,ATM, PALB2 BRCA1, MLH1/MSH2 start at age 45 or 50 or 10 years younger than youngest affected blood relative | ||
| ||
H ow ? | ||
At baseline |
| |
During follow-up |
| |
On indication |
|
|
|
| |
|
| |
Intervals and surgery | ||
12 Months |
| |
3 or 6 Months |
| |
Surgery |
| |
| ||
Goals | ||
The goal of surveillance is to detect and treat the following pathological lesions |
| |
|
*Consensus as to when to start surveillance was not reached.
†Literature-based recommendation.
ATM, ataxia telangiectasia mutated; BRCA2, breast cancer 2; CDKN2A, cyclin-dependent kinase inhibitor 2A; CT, computed tomography; EUS, endoscopic ultrasound; FNA, fine-needle aspiration; HbA1c, hemoglobin A1c; IPMN, intraductal papillary mucinous neoplasm; MLH1, mutL homolog 1; MPD, main pancreatic duct; MRI/MRCP, magnetic resonance imaging/magnetic retrograde cholangiopancreatography; MSH2, mutS homolog 2; MSH6, mutS homolog 6; PALB2, partner and localizer of BRCA2; PanIN, pancreatic intraepithelial neoplasia; STK11, serine/ threonine kinase 11.